Astrimmune is committed to developing products to aid in the isolation, detection, identification and characterisation of single cells, especially cancer cells, using minimally invasive techniques. Our scientists have developed Cellexia as part of the study into biomarkers for a number of cancers of unmet need including pancreatic cancer. Cellexia is a high-end engineered filter product for the isolation of individual cells, such as circulating tumour cells, from blood, bodily fluids or disaggregated tissues.
In addition we are also developing fluid flow cell imaging in order to detect unique cells from liquid biopsy samples. We are currently developing a novel system for low cost, non-invasive, monitoring of bladder cancer in previously diagnosed patients, with the aim of avoiding the regular, intrusive cystoscopy currently required for routine monitoring.
Company Details
- Employees
- 2
- Address
- Medicity, Nottingham,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.astrimmune.com
- Keywords
- Filters, CTCs, Cell isolation, Oncology.
- HQ
- Nottingham
Astrimmune Ltd Questions
Astrimmune Ltd's website is http://www.astrimmune.com
Astrimmune Ltd's LinkedIn profile is https://uk.linkedin.com/company/astrimmune
Astrimmune Ltd has
2 employees.
View email and phone details for 2
employees at Astrimmune Ltd.
Astrimmune Ltd's industry is
Biotechnology Research
Astrimmune Ltd's top competitors are
Gilead Sciences,
Future Diagnostics Solutions,
The Binding Site,
Ecolab,
Microbiotix, Inc,
Nbcl - Novel Biomarkers Catalyst Lab,
Sterling Engineering,
Amgen.
Astrimmune Ltd's categories are Biotechnology Research
